durvalumab

• 

Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?

By Sharon Deveson Kell|2022-06-08T10:28:09+00:008 Jun 2022|Drug treatments|

At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]

Read More

Comments Off on Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?

• 

MEDI0680 plus durvalumab compared to nivolumab in patients with advanced kidney cancer

By Sharon Deveson Kell|2022-05-11T07:43:47+00:0011 May 2022|Drug treatments|

MEDI0680 and durvalumab are both immunotherapies called checkpoint inhibitors. They [...]

Read More

Comments Off on MEDI0680 plus durvalumab compared to nivolumab in patients with advanced kidney cancer

• 

ASCO GU 2020: Overall survival results for savolitinib and durvalumab in papillary kidney cancer

By Sharon Kell|2020-02-21T15:05:41+00:0021 Feb 2020|Drug treatments|

Overall survival results from a study with a combination of [...]

Read More

Comments Off on ASCO GU 2020: Overall survival results for savolitinib and durvalumab in papillary kidney cancer

• 

Combination PD-1 and PD-L1 inhibitors for kidney cancer are no more beneficial than PD-1 inhibitor alone

By Sharon Kell|2019-11-20T10:02:53+00:0020 Nov 2019|Drug treatments|

A recent phase II clinical trial has shown that combined [...]

Read More

Comments Off on Combination PD-1 and PD-L1 inhibitors for kidney cancer are no more beneficial than PD-1 inhibitor alone

• 

ASCO GU 2019: Savolitinib and durvalumab in metastatic papillary kidney cancer

By Sharon Kell|2019-02-26T12:31:40+00:0026 Feb 2019|Drug treatments|

Results from this trial for papillary renal cell carcinoma (RCC) [...]

Read More

Comments Off on ASCO GU 2019: Savolitinib and durvalumab in metastatic papillary kidney cancer